Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer

BACKGROUND: Triple-negative breast cancers (TNBCs), especially those non-immune-inflamed tumors, have a poor prognosis and limited therapies. Human leukocyte antigen (HLA)-I not only contributes to antitumor immune response and the phenotype of the tumor microenvironment, but also is a negative pred...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yi-Fan, Xiao, Yi, Jin, Xi, Di, Gen-Hong, Jiang, Yi-Zhou, Shao, Zhi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496394/
https://www.ncbi.nlm.nih.gov/pubmed/34615706
http://dx.doi.org/10.1136/jitc-2021-003371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496394/
https://www.ncbi.nlm.nih.gov/pubmed/34615706
http://dx.doi.org/10.1136/jitc-2021-003371

Ejemplares similares